Overall rank by patents
#30,872
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Akeso Biopharma, Inc.
USPTO PatentsView assignee record - 8 granted patents across 5 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C07K (PEPTIDES).
8
Total patents granted
5
CPC technology areas
19.8
Avg claims per patent
+600%
5-year filing velocity
The verdict
Akeso holds 8 US patents across 5 technology areas, rank #30,872 of 50,000 tracked assignees.
- #30,872
- of 50,000 US assignees by volume
- Top 54%
- by Innovation Score (34.0/100)
- 19.8
- avg claims per patent
- +600%
- filing velocity, last 5 yrs
Portfolio overview
Akeso Biopharma, Inc. has been granted 8 US utility patents between 2019 and 2025, placing Akeso Biopharma, Inc. at rank #30,872 across all assignees tracked by PlainPatent. This portfolio spans 5 distinct Cooperative Patent Classification (CPC) subclasses, averaging 19.8 claims per patent with primary concentration in C07K (PEPTIDES). As a Foreign Corporation, Akeso Biopharma, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Akeso sits between Airborne International B.v. (8 patents, rank #30,868) and Algoblu Holdings Limited (8 patents, rank #30,876) - the closest US assignees by grant volume. The composite Innovation Score of 34.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 1 in the 2015–2019 window, a +600% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Akeso Biopharma, Inc.'s 19.8 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 5 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Akeso Biopharma, Inc. against peers pursuing similar technology classes.
Who files at Akeso's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Airborne Internat…
Airborne International B.V.
8 patents
- Airguard
Airguard Ltd.
8 patents
- Airhawk Internati…
Airhawk International, LLC
8 patents
- Akagera Medicines
Akagera Medicines, Inc.
8 patents
- Aktina
Aktina Corp.
8 patents
- Alakai Defense Sy…
Alakai Defense Systems, Inc.
8 patents
- Alation
Alation, Inc.
8 patents
- Algoblu Holdings
Algoblu Holdings Limited
8 patents
- Akeso Biopharma ◀
Akeso Biopharma, Inc.
8 patents
What this shows Akeso holds 8 patents at rank #30,872, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Akeso
By rank, the assignees closest to #30,872 in granted patent volume.
- Airborne International B.v. #30,868 · 8 patents
- Airguard Ltd. #30,869 · 8 patents
- Airhawk International, Llc #30,870 · 8 patents
- Akagera Medicines, Inc. #30,871 · 8 patents
- Aktina Corp. #30,873 · 8 patents
- Alakai Defense Systems, Inc. #30,874 · 8 patents
- Alation, Inc. #30,875 · 8 patents
- Algoblu Holdings Limited #30,876 · 8 patents
Leaders in C07K (Peptides)
Other assignees with the most granted patents in Akeso's primary technology class.
- The Regents Of The University Of California 894 in class
- Regeneron Pharmaceuticals, Inc. 824 in class
- Immatics Biotechnologies Gmbh 678 in class
- Genentech, Inc. 565 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 513 in class
- The Trustees Of The University Of Pennsylvania 501 in class
- Novartis Ag 407 in class
- The Board Of Trustees Of The Leland Stanford Junior University 400 in class
Akeso's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
34 Top 54% higher than 46% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 1 | 12.5% |
| 2020 | 1 | 12.5% |
| 2021 | 1 | 12.5% |
| 2022 | 2 | 25.0% |
| 2023 | 1 | 12.5% |
| 2025 | 2 | 25.0% |
Which technologies does Akeso Biopharma, Inc. patent most?
Top 5 of 5 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Standard
Velocity Accelerating
Frequently Asked Questions
How many patents does Akeso Biopharma, Inc. hold?
Akeso Biopharma, Inc. holds 8 US granted patents filed between 2019 and 2025, spanning 5 technology areas.
What is Akeso Biopharma, Inc.'s Innovation Score?
Akeso Biopharma, Inc. has an Innovation Score of 34.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Akeso Biopharma, Inc. focus on?
Akeso Biopharma, Inc.'s top technology area is C07K (PEPTIDES) with 8 patents. The company has filed patents in 5 CPC subclasses total.
Is Akeso Biopharma, Inc.'s patent filing rate increasing or decreasing?
Akeso Biopharma, Inc.'s recent filing velocity is +600% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Akeso Biopharma, Inc.'s patents?
Akeso Biopharma, Inc.'s patents average 19.8 claims each. This falls within the standard range, providing solid legal coverage.
How is the Akeso Biopharma, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Akeso's 8 grants land it in the top 54% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Akeso ranks #30,872 of 50,000. Top 50 holders
- Most of this portfolio concentrates in C07K - see who else leads that technology area. C07K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.